Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review

Bibliography

• Viberti G, Lachin J, Holman R, A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabet Med 2006;23:1289–94
   PubMed Web of Science ®Google Scholar
• Matthews DR, Cull CA, Stratton IM, UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297–303
   PubMed Web of Science ®Google Scholar
• Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3–19
   PubMed Web of Science ®Google Scholar
• Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005;36:197–209
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Ferrannini E, Miyazaki Y, Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004;47:31–9
   PubMed Web of Science ®Google Scholar
• Lamberts EJ, Nijpels G, Welschen LM, Long term patterns of use after initiation of oral antidiabetic drug therapy. Pharmacoepidemiol Drug Saf 2011;20:351–8
   PubMed Web of Science ®Google Scholar
• Goldman-Levine JD. Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus. Pharmacotherapy 2011;31:44S–53S
   PubMed Web of Science ®Google Scholar
• Tzefos M, Olin JL. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother 2010;44:1294–300
   PubMed Web of Science ®Google Scholar
• Perfetti R. Combining basal insulin analogs with glucagon-like peptide-1 mimetics. Diabetes Technol Ther 2011;13:873–81
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103–12
   PubMed Web of Science ®Google Scholar
• Iltz JL, Baker DE, Setter SM, Keith CR. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006;28:652–65
   PubMed Web of Science ®Google Scholar
• Wysham C, Bergenstal R, Malloy J, DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011;28:705–14
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301–10
   PubMed Web of Science ®Google Scholar
• Diamant M, Van GL, Stranks S, Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234–43
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, MacConell L, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431–9
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255–61
   PubMed Web of Science ®Google Scholar
• Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009;11(Suppl 3):26–34
   PubMed Web of Science ®Google Scholar
• Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 1997;105:187–95
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716–30
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The Treat-to-target trial. Diabetes Care 2003;26:3080–6
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35:S11–63
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203
   PubMed Web of Science ®Google Scholar
• Pamphlet/product. Byetta prescribing information. Eli Lilly and Co; Indianapolis, IN: 2011
   Google Scholar
• Heine RJ, Van Gaal LF, Johns D, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559–69
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259–67
   PubMed Web of Science ®Google Scholar
• Pamphlet/product. Victoza prescribing information. Novo-Nordisk; Princeton, NJ: 2011
   Google Scholar
• Pamphlet/product. Bydureon prescribing information. Amylin Pharmaceuticals; San Diego, CA: 2012
   Google Scholar
• Buse JB, Rosenstock J, Sesti G, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240–50
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 2011;71:1675–88
   PubMed Web of Science ®Google Scholar
• Davis SN, Johns D, Maggs D, Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007;30:2767–72
   PubMed Web of Science ®Google Scholar
• Sheffield CA, Kane MP, Busch RS, Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285–92
   PubMedGoogle Scholar
• Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511–23
   PubMed Web of Science ®Google Scholar
• Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012;6:41–6
   PubMed Web of Science ®Google Scholar
• Price HC, Gorst C, Ayyagari U, Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice. Pract Diabetes 2012;29:61–4
   Google Scholar
• Ryder R, Thong K, Cull M, The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diab Int 2010;27:352–357b
   Google Scholar
• Thong KY, Jose B, Sukumar N, Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. Diabetes Obes Metab 2011;13:703–10
   PubMed Web of Science ®Google Scholar
• Thong KY, Jose B, Blann AD, Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract 2011;93:87–91
   PubMed Web of Science ®Google Scholar
• Arnolds S, Dellweg S, Clair J, Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010;33:1509–15
   PubMed Web of Science ®Google Scholar
• Bain SC, Devries JH, Seufert J, 2012
   Google Scholar
• Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid 2011;6:67–79
   PubMedGoogle Scholar
• Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948–61
   PubMed Web of Science ®Google Scholar
• Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005;28:1245–9
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523–34
   PubMed Web of Science ®Google Scholar
• Davis RE, Morrissey M, Peters JR, Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21:1477–83
   PubMed Web of Science ®Google Scholar
• Hermanides J, Vriesendorp TM, Bosman RJ, Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010;38:838–42
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Behle K, Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239–46
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758–67
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–74
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408–16
   PubMed Web of Science ®Google Scholar
• Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007;30:1127–42
   PubMed Web of Science ®Google Scholar
• Meneghini LF, Orozco-Beltran D, Khunti K, Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011;96:3337–53
   PubMed Web of Science ®Google Scholar
• Jendle J, Nauck MA, Matthews DR, Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163–72
   PubMed Web of Science ®Google Scholar
• Nayak UA, Govindan J, Baskar V, Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010;103:687–94
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301–10
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck MA, Forst T, Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Diabetologia 2011;54(Suppl):OP13
   Google Scholar
• Elashoff M, Matveyenko AV, Gier B, Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150–6
   PubMed Web of Science ®Google Scholar
• Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349–54
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019–27
   PubMed Web of Science ®Google Scholar
• Dore DD, Bloomgren GL, Wenten M, A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13:559–66
   PubMed Web of Science ®Google Scholar
• Zealand Pharma announces additional positive results for lixisenatide (Lyxumia®1) from the global GetGoal Phase III program in Type 2 Diabetes. Zealand Pharma. 2012. Available from: http://ir.zealandpharma.com/releasedetail.cfm?ReleaseID=647087 [Last accessed 19 March 2012]
   Google Scholar